Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parexel International, a US-based clinical research organization (CRO), has acquired all of the outstanding equity securities of privately-owned ClinIntel, a UK-based provider of clinical Randomization and Trial Supply Management (RTSM) services.
Subscribe to our email newsletter
The acquisition will see ClinIntel’s offerings combined into the ClinPhone RTSM suite and are designed to make patient randomization and clinical supply chain solutions more efficient.
ClinIntel’s capabilities include advanced RTSM technologies for planning, forecasting and supply chain eLogistics.
The complete ClinPhone RTSM suite will be available as a standalone solution through the Perceptive MyTrials platform, and both solutions will be available through the Perceptive Partner Program.
Parexel International chairman and CEO Josef von Rickenbach said as the use of technology has expanded in the conduct of clinical research, the company has been a leader in Randomization and Trial Supply Management.
"By combining the trial supply management technologies from ClinIntel with our existing ClinPhone solutions, we believe we have an opportunity to further advance our position as a clinical technology leader and grow market share by bringing enhanced speed, efficiency, and simplicity to our RTSM offering," von Rickenbach said.
Founded in 2009, ClinIntel works with biopharmaceutical companies and CROs and the acquired business will be integrated into the Parexel Informatics segment.